Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios. (September 2018)

• Record Type: Journal Article
• Authors: Chang, Ting-Yung; Liao, Jo-Nan; Chao, Tze-Fan; Vicera, Jennifer Jeanne; Lin, Chin-Yu; Tuan, Ta-Chuan; Lin, Yenn-Jiang; Chang, Shih-Lin; Lo, Li-Wei; Hu, Yu-Feng; Chung, Fa-Po; Chen, Shih-Ann
• Is Part Of: IJC heart & vasculature. Volume 20(2018)
• Page Start: 56
• Page End: 62
• Publication Date: 2018-09
• Subjects: Atrial fibrillation -- Oral anticoagulation -- Chronic kidney disease -- Coronary intervention -- Valvular heart disease; Cardiovascular system -- Diseases -- Periodicals; Cardiovascular system -- Pathophysiology -- Periodicals; 616.1005
• DOI: 10.1016/j.ijcha.2018.08.003
• Languages: English
• ISSNs: 2352-9067

Abstract

Abstract: Atrial fibrillation (AF) has become the most prevalent arrhythmia and it will increase the risk of ischemic stroke, heart failure, mortality, sudden cardiac death, myocardial infarction, and dementia. Stroke prevention with oral anticoagulant is crucial for management of AF patients. Vitamin K antagonist, which inhibits the clotting factors II, VII, IX and X, has been recommended for stroke prevention for decades. Non-Vitamin K antagonist oral anticoagulants (NOACs), including dabigatran, rivaroxaban, apixaban and edoxaban are at least as effective as warfarin in reducing ischemic stroke with a lower rate of major bleeding. With the increasing prevalence of AF, prescription of the appropriate oral anticoagulants (OACs) according to patient's characteristics becomes a challenge. This review article aims to provide an overview of anticoagulant use in AF patients with difficult scenarios.